You are here:

oestrogens, conjugated, bazedoxifene acetate (Duavive)

Advice

in the absence of a submission from the company

oestrogens, conjugated, bazedoxifene acetate (Duavive®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate.

The company has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: oestrogens, conjugated, bazedoxifene acetate (Duavive)
SMC Drug ID: 1220/17
Manufacturer: MSD Limited / Pfizer Limited
Indication: Treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate.
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 16 January 2017

Back